This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Identification of genes and pathways potentially related to PHF20 by gene expression profile analysis of glioblastoma U87 cell line
Cancer Cell International Open Access 04 October 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Landau DA, Carter SL, Getz G, Wu CJ . Clonal evolution in hematological malignancies and therapeutic implications. Leukemia 2014; 28: 34–43.
Lasho T, Johnson SH, Smith DI, Crispino JD, Pardanani A, Vasmatzis G et al. Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing. Am J Hematol 2013; 88: 741–746.
Cui G, Park S, Badeaux AI, Kim D, Lee J, Thompson JR et al. PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53. Nat Struct Mol Biol 2012; 19: 916–924.
Park S, Kim D, Dan HC, Chen H, Testa JR, Cheng JQ . Identification of Akt interaction protein PHF20/TZP that transcriptionally regulates p53. J Biol Chem 2012; 287: 11151–11163.
Li Y, Park J, Piao L, Kong G, Kim Y, Park KA et al. PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage. Cell Signal 2013; 25: 74–84.
Smith ML, Seo YR . p53 regulation of DNA excision repair pathways. Mutagenesis 2002; 17: 149–156.
Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 2010; 24: 1389–1402.
Harutyunyan A, Klampfl T, Cazzola M, Kralovics R . p53 lesions in leukemic transformation. N Engl J Med 2011; 364: 488–490.
Peller S, Rotter V . TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 2003; 21: 277–284.
Kumagai T, Tefferi A, Jones L, Koeffler HP . Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia. Leuk Res 2005; 29: 511–515.
Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002; 277: 21843–21850.
Nakatake M, Monte-Mor B, Debili N, Casadevall N, Ribrag V, Solary E et al. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene 2012; 31: 1323–1333.
Khan I, Huang Z, Wen Q, Stankiewicz MJ, Gilles L, Goldenson B et al. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia 2013; 27: 1882–1890.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Lasho, T., Pardanani, A., Tefferi, A. et al. Altered expression of tumor suppressor PHF20 in myeloproliferative neoplasms. Leukemia 28, 1762–1764 (2014). https://doi.org/10.1038/leu.2014.117
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.117
This article is cited by
-
Identification of genes and pathways potentially related to PHF20 by gene expression profile analysis of glioblastoma U87 cell line
Cancer Cell International (2017)